Join
us as our speakers discuss march-in rights and compulsory licenses. Recent
events like governmental agencies turning to march-in as a potential means to
lower drug pricing or the pandemic have refueled the discussion on compulsory
licenses here and in Europe. Our speakers will review the history of the Bayh
Dole act as well as compulsory licenses in Europe and provide an overview of
recent developments in both jurisdictions. Finally, the speakers touch on the
implications and concerns for patent holders and future innovation in the
biopharma space here and in Europe.
Presented by:
Christine Kanz, Hoyng Rokh Monegier
Joanna Brougher, BioPharma Law Group, PLLC
AIPLA is an approved provider by most jurisdictions requiring CLE. Each program requires individual jurisdiction approval, and each jurisdiction has different approval guidelines and time frames so programs may not be pre-approved for CLE. Program accreditation is sought in all attendee requested US jurisdictions and may be available for up to one year after the original air date. Specialized credits (Ethics, Elimination of Bias, Diversity, Equity & Inclusion, Technology, etc.) approval varies by jurisdiction. CLE reporting and/or certificates of attendance may take up to 4 weeks for processing. For information on CLE accreditation and processing, please contact the AIPLA CLE Department at cle@aipla.org.